CorrespondenceCannabidiol in patients with treatment-resistant epilepsy – Authors' reply
Reference (1)
- et al.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Lancet Neurol
(2016)
Cited by (14)
Cannabidiol – A new fixture in childhood neurology
2021, Current Opinion in PharmacologyCitation Excerpt :Future studies will need to examine the long-term effects on the developing brain of children, the relationship between clinical response and plasma concentrations, drug-to-drug interactions, and the potential for use in other childhood epilepsy syndromes such as Doose Syndrome, Infantile spasms, Rasmussen Syndrome, and related. An open-label trial [14] suggested that CBD may have beneficial effects on patient quality of life, distinct from its seizure-reducing effects. This paralleled a review of children with severe epilepsies treated with artisanal CBD preparations, where a majority reported improved mood, behavior, language, alertness, and sleep [15,16].
Application of conventional and high-pressure extraction techniques for the isolation of bioactive compounds from the aerial part of hemp (Cannabis sativa L.) assortment Helena
2021, Industrial Crops and ProductsCitation Excerpt :The main cannabinoid present in the industrial hemp is cannabidiol (CBD) (Brighenti et al., 2017). CBD is a valuable compound because it possesses various pharmacological activities such as antioxidant and anti-inflammatory (Atalay et al., 2020), neuroprotective (Hampson et al., 1998), anxiolytic (Schier et al., 2012), antiepileptic (Devinsky et al., 2016), antifungal and antibacterial (Klingeren and Ham, 1976; McPartland, 1984). Beside of CBD, many authors also reported that industrial hemp is a suitable source of polyphenols (Mkpenie et al., 2012; Frassinetti et al., 2018; Fathordoobady et al., 2019; Nagy et al., 2019).
Rett Syndrome: A Timely Review From Recognition to Current Clinical Approaches and Clinical Study Updates
2021, Seminars in Pediatric NeurologyCitation Excerpt :Cannabidiol (trade name Epidiolex) was approved by the Food and Drug Administration (FDA) as an anticonvulsant for refractory epilepsies including Lennox Gastaut, Dravet syndrome, and Tuberous Sclerosis. Although the exact mechanism of action in seizure reduction is not yet known, cannabidiol has been shown to modify the excitatory and inhibitory imbalance of neurons as demonstrated by anticonvulsant activity in refractory epilepsy syndromes.69–71 Additionally, a cannabinoid structurally similar to cannabidiol known as cannabidivarin led to brain alterations and improved behaviors in a Mecp2 mutant mouse.72
Dravet Syndrome: A Review of Current Management
2020, Pediatric NeurologyEfficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam
2020, Epilepsy ResearchCitation Excerpt :This would suggest that the efficacy of CBD has been overestimated (Devinsky et al., 2016a). Although the study maintained that CBD may still be effective in controlling seizures, critics have questioned whether the entire efficacy of CBD could be attributed to the associated increase in nCLB levels (Devinsky et al., 2016b; Mandelbaum, 2016). Previous research by Porcari et al. and Pietrafusa et al. suggests that artisanal CBD is effective as an adjunctive treatment for refractory epilepsy in pediatric populations, both with and without concomitant CLB use.